# Rituximab and Bendamustine in Very Elderly Patients or Elderly Medically Non Fit Patients With Aggressive B-cell Lymphoma

> **NCT01686321** · PHASE2 · COMPLETED · sponsor: **University of Göttingen** · enrollment: 68 (actual)

## Conditions studied

- Aggressive Lymphoma

## Interventions

- **DRUG:** Bendamustine and subcutaneous rituximab

## Key facts

- **NCT ID:** NCT01686321
- **Lead sponsor:** University of Göttingen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07-04
- **Primary completion:** 2018-08-08
- **Final completion:** 2018-08-08
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2018-12-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01686321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01686321, "Rituximab and Bendamustine in Very Elderly Patients or Elderly Medically Non Fit Patients With Aggressive B-cell Lymphoma". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT01686321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*